Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00726-010-0496-4 http://scihub22266oqcxt.onion/10.1007/s00726-010-0496-4 C4041611!4041611!20509035     free     free     free       Amino+Acids 2011 ; 41 (4): 893-9 Nephropedia Template TP {{tp|p=20509035|t=2011. S100P: a novel therapeutic target for cancer |pdf=|usr=}}{{20509035}} gab.com Text S100P: a novel therapeutic target for cancer JO: Amino Acids http://www.kidney.de/pget.php?&tw=1&pmid=20509035 #FOAvip S100P expression is described in many different cancers, and its expression is associated with drug resistance, metastasis, and poor clinical outcome. S100P is member of the S100 family of small calcium-binding proteins that have been reported to have either intracellular or extracellular functions, or both. Extracellular S100P can bind with the receptor for advanced glycation end products (RAGE) and activate cellular signaling. Through RAGE, S100P has been shown to mediate tumor growth, drug resistance, and metastasis. S100P is specifically expressed in cancer cells in the adult. Therefore, S100P is a useful marker for differentiating cancer cells from normal cells, and can aid in the diagnosis of cancer by cytological examination. The expression of S100P in cancer cells has been related to hypomethylation of the gene. Multiple studies have confirmed the beneficial effects of blocking S100P/RAGE in cancer cells, and different blockers are being developed including small molecules and antagonist peptides. This review summarizes the role and significance of S100P in different cancers. Twit Text FOAVip S100P: a novel therapeutic target for cancer ????Amino Acids http://www.kidney.de/pget.php?&tw=1&pmid=20509035 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=20509035 #FOAvip English Wikipedia <ref>{{Cite pmid|20509035}}</ref> S100P: a novel therapeutic target for cancer #MMPMID20509035 Arumugam T; Logsdon CD Amino Acids 2011[Oct]; 41 (4): 893-9 PMID20509035show ga S100P expression is described in many different cancers, and its expression is associated with drug resistance, metastasis, and poor clinical outcome. S100P is member of the S100 family of small calcium-binding proteins that have been reported to have either intracellular or extracellular functions, or both. Extracellular S100P can bind with the receptor for advanced glycation end products (RAGE) and activate cellular signaling. Through RAGE, S100P has been shown to mediate tumor growth, drug resistance, and metastasis. S100P is specifically expressed in cancer cells in the adult. Therefore, S100P is a useful marker for differentiating cancer cells from normal cells, and can aid in the diagnosis of cancer by cytological examination. The expression of S100P in cancer cells has been related to hypomethylation of the gene. Multiple studies have confirmed the beneficial effects of blocking S100P/RAGE in cancer cells, and different blockers are being developed including small molecules and antagonist peptides. This review summarizes the role and significance of S100P in different cancers. äS100P: a novel therapeutic target for cancer (epmc).pdf DeepDyve Pubget Overpricing